NEC Bio Therapeutics Unveils Promising Results for AI-Powered Oral Cancer Vaccine

NEC Bio Therapeutics has announced promising interim results from its Phase 1 clinical trial of NECVAX-NEO1, an innovative AI-driven oral cancer vaccine, at the ESMO Immuno-Oncology Congress. This groundbreaking vaccine targets solid tumors and has shown a high disease control rate among participants, indicating its potential as a personalized treatment option for challenging cancers.